New Immune-Targeting drug surovatamig enters first human tests for arthritis and lupus
NCT ID NCT07201558
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tests surovatamig, a bispecific T-cell engager, in 48 adults with rheumatoid arthritis or systemic lupus erythematosus. The study gives the drug as injections in increasing doses to check safety, side effects, and how the body processes it. It is too early to know if it works, but the goal is to find a safe dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
surovatamig
What this could lead to
If this early trial shows safety, it could lead to a new treatment option for rheumatoid arthritis and lupus by targeting specific immune cells.
What could go wrong
This is a very early Phase 1 study with only 48 participants, so it is primarily checking safety, not effectiveness. The drug may cause side effects or fail to work in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
WITHDRAWNBirmingham, Alabama, 35233, United States
-
Research Site
RECRUITINGFullerton, California, 92835, United States
-
Research Site
RECRUITINGAllen, Texas, 75013, United States
-
Research Site
RECRUITINGBirtinya, 4575, Australia
-
Research Site
NOT_YET_RECRUITINGClayton, 3168, Australia
-
Research Site
NOT_YET_RECRUITINGAntwerp, 2020, Belgium
-
Research Site
NOT_YET_RECRUITINGPorto Alegre, 90035-903, Brazil
-
Research Site
NOT_YET_RECRUITINGBeijing, 100034, China
-
Research Site
NOT_YET_RECRUITINGNanjing, 210008, China
-
Research Site
NOT_YET_RECRUITINGBonn, 53127, Germany
-
Research Site
NOT_YET_RECRUITINGMainz, 55131, Germany
-
Research Site
NOT_YET_RECRUITINGMünchen, D-80336, Germany
-
Research Site
NOT_YET_RECRUITINGBarcelona, 08025, Spain
-
Research Site
NOT_YET_RECRUITINGCórdoba, 14004, Spain
-
Research Site
NOT_YET_RECRUITINGMadrid, 28034, Spain
-
Research Site
NOT_YET_RECRUITINGKaohsiung City, 83301, Taiwan
-
Research Site
RECRUITINGKyiv, 04050, Ukraine
-
Research Site
RECRUITINGTernopil, 46002, Ukraine
-
Research Site
RECRUITINGVinnytsia, 21018, Ukraine